Kelly Services, Inc. (NASDAQ:KELYA) last session’s volume of 0.23 million shares was higher than its average volume of 0.13 million shares. The stock, after opening at $24.15, hit $24.06 through the close by scoring -0.5%.

Kelly Services, Inc. (KELYA) Analyst Opinion

Kelly Services, Inc. has a consensus hold rating from 1 Wall Street analysts, and the number of shares currently sold short amount to at least 1.67% of shares outstanding. The stock spiked 12.69% last month and is up 5.34 this year. Wall Street is only getting neutral on the stock, with 0 of analysts who cover KELYA having a buy-equivalent rating. Analysts have placed a $21 price target on Kelly Services, Inc., suggesting a -12.72% decline from recent close. It’s currently trading about -1.47% below its 52-week high.

Kelly Services, Inc. Earnings Surprise

Kelly Services, Inc. (KELYA) revenue totaled $1.28 billion down -2.14% from the previous quarter.

Kelly Services, Inc. (NASDAQ:KELYA) Intraday View

This stock (KELYA) is ahead of its 52-week low with 34.69%. Its last month’s stock price volatility remained 4.62% which for the week stands at 3.26%. The share price has moved forward from its 20 days moving average, trading at a distance of 7.46% and stays 10.92% away from its 50 days moving average. Over the last five days, shares have managed 5.07% gains and now is up 15.9% since hitting its 200-day moving average of $21.63. Kelly Services, Inc. (KELYA) has made its way to a 12-month gain of 31.24%.

Turning to Intellia Therapeutics Inc. (NASDAQ:NTLA), its shares were trading at $14.35 a gain of $0.45, on the trading floor. The stock, after opening at $13.94, touched a high of $14.4 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.5. Intellia Therapeutics Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -52.8% from its high of $30.4 to a $491.63 million market value through last close.

Intellia Therapeutics Inc. (NTLA) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.5 to 1.5 during a month. Analysts set a 12-month price target of $24.25 a share. The target implies a 68.99% spike from where the shares are currently trading. Also, the current price highlights a discount of 171.78% to analysts’ high consensus price target.

Intellia Therapeutics Inc. (NASDAQ:NTLA) Intraday Trading

The counter witnessed a trading volume of 0.11 million shares versus an average volume of 0.19 million shares during last trading session. Its last month’s stock price volatility remained 4.81% which for the week approaches 4.92%. The lowest price the stock reached in the last trading day was $13.94 and compares with the $10.83 52-week low. The stock recovered 32.5% since its low point and has performed 9.46% year-to-date.